公司资料
REGENXBIO Inc. 股价、新闻与催化剂
- 股票代码:
- RGNX
- 交易所:
- NASDAQ
- 行业:
- Biopharma
- 所在地:
- United States
股票表现
7.88 USD (-1.87%)
收盘价
最后更新: 2026年9月21日
337M USD
市值
股价为何变动
截至 2026年9月21日，RGNX 下跌 1.87%，收于 $7.88。当前新闻监测窗口内未发现新的同公司新闻。
公司概览
业务概览
REGENXBIO is a gene-therapy company focused on adeno-associated virus platform programs and rare diseases. Its story is built around platform delivery and the commercialization of gene-based medicines.
所在地与行业分类
Headquartered in the United States and listed on NASDAQ, REGENXBIO sits in gene therapy.
商业模式特征
The company depends on clinical validation, manufacturing execution, and the ability to create durable gene-therapy value.
生物医药行业定位
REGENXBIO is a high-catalyst gene-therapy name whose valuation is tied to platform and clinical progress.
未来催化剂
- REGENXBIO's catalysts are its ocular gene-therapy programs and the broader rare-disease pipeline, with the market wanting proof the platform still has staying power. The next update matters if it shows the gene-therapy franchise can keep advancing.
近期新闻
新闻标题由机器翻译，详情为英文原文。
- 01
- 02
- 03
- 04
- 05
相似股票
商业成熟度、治疗领域或催化剂模式相近的同行公司。